HBV markers in haemodialysis Brazilian patients: a prospective 12-month follow-up

Author(s):Show less -

Moreira, Regina Celia ^[1] ; Deguti, Marta Mitiko ^[2] ; Lemos, Marcilio Figueiredo ^[1] ; Saraceni, Claudia Patara ^[1] ; Oba, Isabel Takano ^[1] ; Miranda Spina, Angela Maria ^[1] ; Nescimento-Lima, Alessandra Stilhano ^[2] ; Fares, Jorge ^[3] ; Azevedo, Raymundo Soares ^[4] ; Gomes-Gouvea, Michele Soares ^[2] ; Carrilho, Flair Jose ^[2] ; Rebello Pinho, Joao Renato ^[2]

Affiliation

^[1] Inst Adolfo Lutz Registro, Serv Virol, BR-01246902 Sao Paulo - Brazil

^[2] Univ Sao Paulo, Fac Med, Dept Gastroenterol, LIM 07, Sao Paulo - Brazil

^[3] Univ Sao Paulo, Fac Med, Ctr Hemodialise, Sao Paulo - Brazil

^[4] Univ Sao Paulo, Fac Med, Dept Patol, LIM 01, Sao Paulo - Brazil

• Document type: Journal article
• Source: Memórias do Instituto Oswaldo Cruz; v. 105, n. 1, p. 107-108, FEB 2010.
• Web of Science Citations: 8

Abstract

The aim of this study was to determine the prevalence and the incidence of hepatitis B virus (HBV) among haemodialysis (HD) subjects and to evaluate whether testing for serological markers at the time of admission is suitable for HBV screening in this population. One hundred twenty-three patients belonging to two HD centres from São Paulo, Brazil, were tested prospectively. HBV DNA was detected by polymerase chain reaction (PCR) in each of the prospective subjects (n = 123) during one year. Additionally, all samples (n = 1,476) were analysed for HBV serological markers. The prevalence of hepatitis B core antibody (anti-HBc), hepatitis B surface antigen (HBsAg) and HBV DNA were 34.1%, 15.4% and 8.1%, respectively, while the incidence was null. Fluctuation in HBV serology was observed in one patient. Only 37.8% (17/45) of cases responded to the HBV vaccine. Our results suggest that employing more than one HBV marker and repeated follow-up evaluations may improve HBV screening in HD units. (AU)